MAPT and Alzheimer disease: The benefits of GWAX for enhancing GWAS discovery have been particularly pronounced in the context of late-onset Alzheimer’s Disease (AD) [3–5], a neurocognitive disorder of aging that is clinically characterized by significant cognitive declines that interfere with independence in everyday activities, and biologically characterized by amyloid-predominant neuritic plaques, tau-predominant neurofibrillary tangles, and neurodegeneration [6–10].